Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.51 |
| ▸ | KDM5A | P29375 | 3/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | FABP1 | P07148 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156398 | 0.83 | KDM4C (0.48) | KDM4CKDM5BKDM5AKDM4ADHODH | |
| SCHEMBL16196117 | 0.80 | DHODH (0.70) | DHODHRXRARXRBCTRCFABP1 | |
| SCHEMBL13774513 | 0.79 | P2RX3 (0.52) | — | |
| SCHEMBL3474973 | 0.77 | DHODH (0.59) | DHODHRXRARXRBCTRCFABP1 | |
| SCHEMBL3006814 | 0.77 | RXRA (0.47) | KDM4CDHODHRXRARXRBKDM2B | |
| SCHEMBL30740531 | 0.77 | KDM5A (0.52) | KDM4CKDM5BKDM5AKDM4ARXRA | |
| SCHEMBL940183 | 0.77 | KDM5A (0.52) | KDM4CKDM5BKDM5AKDM4ARXRA | |
| SCHEMBL1495453 | 0.77 | DHODH (0.70) | DHODHRXRARXRBCTRCFABP1 | |
| SCHEMBL3447723 | 0.77 | CYP1A2 (0.54) | KDM4CKDM5BKDM5AKDM4APORCN | |
| SCHEMBL13774498 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440673-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2234976-B1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | KDM4C 3491/4885KDM5B 3616/4885KDM5A 3477/4885 |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | KDM4C 3491/4885KDM5B 3616/4885KDM5A 3477/4885 |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | KDM4C 3491/4885KDM5B 3616/4885KDM5A 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.